Factors Influencing Compliance with Allergen Immunotherapy
Saturday, March 4, 2017: 1:00 PM
Room B302 (Georgia World Congress Center, Building B)
Nicolle Cascone, RN, , ,
Rationale: Allergen immunotherapy (AIT) is currently recommended for a continuous treatment period of 3-5 years [AAAAI practice parameters].  There are likely multiple factors that affect patient compliance in completing the full course of AIT once started.

Methods: We conducted a retrospective chart review of 430 adult patients seen in an Adult University Allergy clinic who started AIT for treatment of allergic rhinoconjunctivitis from June 15, 2004 through June 15, 2014. We compared demographic features, co-morbidities and features specific to environmental allergies between the patients who completed the full course of AIT vs. those who stopped AIT pre-maturely (< 3 years after starting AIT).  Data was analyzed non-parametrically.

Results: In 430 patients started on AIT for environmental allergies, several demographic factors were found in association with non-compliance.   Younger age associated with an increased rate of non-compliance (p=0.00019). Gender is a also a risk factor, with a tendency for a greater percentage of females to pre-maturely discontinue AIT vs. males (54% vs. 44%, p=0.06).  In terms of co-morbidities, vocal cord dysfunction diagnosis associated with a greater rate of pre-mature discontinuation (72% vs. 49%, p=0.0008). Although a prior history of any anaphylaxis associated with AIT non-compliance (p=0.01), systemic reaction to AIT did not impact compliance. The presence of mold in AIT extract was also associated with pre-mature AIT discontinuation (p=0.037).

Conclusions: The data suggests that there are many factors that influence a patient’s compliance in completing the full course of AIT. Health care providers should be aware of these factors when discussing AIT with patients.